Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Head and Neck Neoplasms 4Uterine Cervical Neoplasms 3Tobacco Use Disorder 3Small Cell Lung Carcinoma 3cyclopia sequence 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Smoking Cessation 2Pancreatic Neoplasms 2Overweight 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Obesity 2Nasopharyngeal Neoplasms 2Mouth Neoplasms 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Laryngeal Neoplasms 2Kidney Neoplasms 2Hypopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Vulvar Neoplasms 1

Interventions

repaglinide 1carbon-11 acetate 1Warfarin 1Omeprazole 1Midazolam 1Interviews as Topic 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostate Cancer Patients × Bupropion × Clear all
NCT04664725 2020-12-11

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡